FDA official updates on advancing RWE program, lists common reasons for rejection
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesCBERCDERPharmaceuticalsPharmacovigilanceProduct developmentRegulatory Intelligence/PolicyRWE/RWDUnited StatesUS Food and Drug Administration (FDA)